Evolent Health (NYSE:EVH) Sets New 52-Week Low – Should You Sell?

Evolent Health, Inc. (NYSE:EVH)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as $9.74 and last traded at $9.79, with a volume of 2041320 shares. The stock had previously closed at $10.37.

Analysts Set New Price Targets

A number of equities analysts have commented on EVH shares. BTIG Research dropped their price objective on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, December 3rd. Stephens lowered their target price on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Tuesday, January 21st. Truist Financial lowered their target price on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. JPMorgan Chase & Co. lowered their target price on shares of Evolent Health from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Finally, Royal Bank of Canada lowered their target price on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $18.38.

Evolent Health Stock Up 0.1 %

The business’s fifty day moving average is $11.04 and its two-hundred day moving average is $19.71. The company has a market cap of $1.14 billion, a P/E ratio of -10.76 and a beta of 1.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Thursday, November 7th. The technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The business had revenue of $621.40 million during the quarter, compared to the consensus estimate of $625.58 million. During the same quarter in the prior year, the firm posted $0.19 EPS. Equities analysts predict that Evolent Health, Inc. will post 0.22 EPS for the current year.

Institutional Investors Weigh In On Evolent Health

Several large investors have recently modified their holdings of the business. Wellington Management Group LLP raised its holdings in shares of Evolent Health by 12.8% in the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after purchasing an additional 1,426,747 shares in the last quarter. Eventide Asset Management LLC raised its holdings in shares of Evolent Health by 1.7% in the 3rd quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock valued at $107,580,000 after purchasing an additional 64,985 shares in the last quarter. State Street Corp grew its position in shares of Evolent Health by 1.0% in the 3rd quarter. State Street Corp now owns 2,725,375 shares of the technology company’s stock worth $77,074,000 after buying an additional 25,967 shares during the last quarter. Bellevue Group AG grew its position in shares of Evolent Health by 59.9% in the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock worth $75,509,000 after buying an additional 1,000,215 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Evolent Health by 1,948.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock worth $42,289,000 after buying an additional 1,422,385 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.